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Aims: Catheter ablation (CA) has become standard therapy for atrial fibrillation, especially
for paroxysmal atrial fibrillation. Precise single center follow-up (FU) data (especially long-
term FU data) are published infrequently.
Methods: We studied 303 consecutive patients (172 males, 131 females, mean age 57 years)
who underwent catheter ablation for atrial fibrillation (489 procedures) in years 2004–2012.
Clinical examination, ECG, 24-h or 7-day Holter monitoring and quality of life (QoL)
measurement (EQ-5D) was performed at 3, 6, 12, 18 and 24-month FU.
Results: FU data longer than 6 month after the first procedure are available for 135 patients
with paroxysmal, 84 patients with persistent and 48 patients with longstanding persistent
AF. The success rate after 6 month after the first procedure (sinus rhythm without AA
drugs, no arrhythmias) was 48% for paroxysmal, 43% for persistent and 44% for long-
standing persistent AF. The complication rate was 3.3% (16 patients, no deaths, no
pulmonary vein stenosis, 5 incidents of pericardial effusion treated with pericardiocent-
esis; 1 transitory ischemic attack; the remainder were local complications in the groin).
The success rate after the last procedure (mean FU 24716 month, 1.6 procedure per
patient) was 80% for paroxysmal and 58% for persistent and longstanding persistent AF.
QoL increased significantly in all groups of patients.
Conclusion: With the standard procedure we can achieve acceptable results (success rate
60–80% with repeated procedures) with low complication rate even in a ‘‘lower volume’’
center. In selected patients (with paroxysmal AF preferring interventional treatment) can
be CA recommended as first-line therapy for rhythm control. CA improves QoL in our
patients with AF. As there is no gold standard to measure QoL in AF patients, EQ-5D seems
to be a simple, quick and useful tool.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
.1. Introduction
Catheter ablation (CA) has become standard therapy of atrial
fibrillation (AF), especially for paroxysmal AF. Despite a highch Society of Cardiology.
7; fax: þ420 495 833 017.
an).number of re-ablation procedures (30–50%), success is reported
in 80–95% in patients with paroxysmal AF and 50–85% in
patients with longstanding persistent AF; further, the compli-
cation rate is low (4–6%) [1–3] Precise single center follow-upPublished by Elsevier Urban & Partner Sp.z o.o. All rights reserved..
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infrequently.2. Methods
2.1. Patient characteristics
The group consisted of 303 consecutive patients (172 males,
131 females, mean age 57 years) studied from April 2004
to August 2012. All patients underwent an electrophysiology
study and CA for paroxysmal (157 patients), persistent (dura-
tion 1–12 months, 94 patients) and longstanding persistent
(duration412 months, 52 patients) AF. Patients resistant to
a minimum of two antiarrhythmic (AA) drugs were treated
with catheter ablation until 2006; subsequently, patients
resistant to one AA drug received CA. All patients signed
written informed consent documents.
2.2. Electrophysiological procedure and catheter ablation
Magnetic resonance imaging was performed in all patients
before the procedure (except 4 patients with implanted pace-
maker, where computer tomography was used). AA drugs
were discontinued minimally 5 days (1–3 month for amiodar-
one) before the procedure; in patients with the longstanding
persistent form of AF, amiodarone was usually discontinued
after the procedure. All patients underwent transesophageal
echocardiography within 24 h before the procedure to
exclude thrombi in the left atrial appendage. All patients
received effective oral anticoagulation for at least 4 weeks
before ablation. Low molecular weight heparin (LMWH) antic-
oagulation replaced oral anticoagulants 2–3 days before CA.
Patients were studied in a conscious state with analgoseda-
tion (fentanyl and diazepam intravenously until 2010; subse-
quently fentanyl, diazepam and propofol intravenously). A
decapolar catheter was inserted through the right femoral
vein into the coronary sinus. Two long sheaths (FAST-CATH
Transseptal, 8.5 F, SJM, Minnetonka, MN; PREFACE 8F, Bio-
sense Webster Inc., Diamond Bar, CA) were inserted to the
left atrium transseptally, via the right femoral vein. After the
last femoral vein puncture, an intravenous bolus of heparin
(5000 units) was administered. After the first transseptal
puncture, an additional intravenous bolus of heparin (dose
complementary to 100 unit per kg) followed by infusion or
additional boluses to maintain an activated clotting time of
300–350 s.
All procedures were done by one operator. Electroanatomi-
cal maps of the left atrium were constructed using a non-
fluoroscopic navigation system (CARTO XP, CARTO 3 from
March 2011, Biosense Webster Inc., Diamond Bar, CA) in all
patients. Radiofrequency (RF) lesions were delivered with an
irrigated-tip catheter (Navistar Thermocool, Biosense Web-
ster Inc.). RF energy was titrated up to 25 W (to 23 W on the
posterior wall); the irrigation rate was 20 ml/min. Ablation
lesions created circumferential lines around the antra (ostia)
of the pulmonary veins (PV) in patients with paroxysmal AF;
in persistent and longstanding persistent AF patients, addi-
tional ablation lines were created (roof line, mitral isthmus
line). In some patients ablation of fractionated electrogramsand ablation inside the coronary sinus was performed. The
endpoint of the PVablation was PV isolation confirmed with a
circular catheter (LASSO, Biosense Webster Inc. or Optima
Plus, IBI, St. Jude Medical, Minnetonka, MN). The endpoint of
linear and substrate ablation was termination of AF (directly
or via left atrial flutter) or completion of these lines after
electrical cardioversion in patients who were still in AF at the
end of ablation.
2.3. Post-ablation management
All patients were discharged on oral anticoagulants and
continued this therapy for at least 2–3 months. Clinical
examination, ECG and 24-h or 7-day Holter monitoring was
performed at 3, 6, 12, 18 and 24-month FU. AA drug therapy
was discontinued 1–3 months after the procedure (if it was
not discontinued before the procedure). Patients with recur-
rent AF underwent re-ablation 6 months after the first
procedure.
2.4. Quality-of-life measurement
Quality of life was measured prospectively with the European
Quality of Life Group instrument—EQ-5D, Czech version. The
objective portion, EQ-5D index, measures mobility, self-care,
usual activities, pain/discomfort and anxiety/depression on a
0–1 scale using the European value set [4]; the subjective
portion, EQ VAS (visual analog scale of 0–100) was measured
before CA and during FU visits; in cases of re-ablation,
measurements were re-initiated.
2.5. Statistical analysis
Continuous measurements are presented as the mean7
standard deviation. Data obtained before and during the
follow-up were compared by means of Students t-test or
Kruskal–Wallis Multiple-Comparison Z-Value Test (using
NCSS statistical programme). A p-valueo0.05 was considered
statistically significant.3. Results
3.1. Magnetic resonance imaging results
3D reconstruction proved in 80% of our patients common
ostium of left sided PV (dominantly shorter-1–2 cm, in 18%
longer than 2 cm). In 6% of patients was proved accessory
right middle PV. 6% of patients had common ostium of
left and right sided PV. In one patient was proved common
ostium oft left sided PV and right inferior PV from the
posterior wall.
3.2. Transesophageal echocardiography results
311 patients underwent transesophageal echocardiography
day before the procedure. In two patients was CA canceled
because of thrombus in atrial appendage. In 6 patients was
newly diagnosed severe mitral or aortic regurgitation and
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procedure.
3.3. Procedural data
From April 2004 to August 2012 catheter ablation of AF under-
went 303 patients, including redo procedures was performed
totally 489 procedures (1.6 procedure per patient, Fig. 1).
Mean time of all procedures was 249 min (115–420), mean
x-ray time was 19 min (3–97); Figs. 2 and 3.
3.4. Clinical characteristic
CA for paroxysmal AF was performed in 157 pt (mean age 57
years), for persistent AF in 94 patients (mean age 58 years)
and for longstanding persistent AF in 52 patients (mean age
57 years). Duration of symptoms, previous antiarrhythmic
drug therapy, type of symptoms, echocardiographic para-
meters and concomitant diseases are shown in Table 1.
3.5. Complications
The complication rate was 3.3% (16 patients, no deaths, no
pulmonary vein stenosis, 5 incidents of pericardial effusion0
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Fig. 2 – Mean time of the procedure.treated with pericardiocentesis; 1 transitory ischemic attack;
the remainder were local complications in the groin, Table 2).
Four pericardial effusions became symptomatic within 2–6 h
after the end of the procedure, in one patient was observed
late tamponade more than 48 h after the procedure. Three
out of the local complications in the groin were treated
surgically. All complications were treated successfully with-
out any further consequences.3.6. Catheter ablation results
Serial Holter monitoring was performed in all patients, in 15%
of patients was also performed 7-day Holter monitoring.
FU data longer than 6 month after the first procedure are
available for 135 patients with paroxysmal, 84 patients with
persistent and 48 patients with longstanding persistent AF.
The success rate after 6 month after the first procedure
(defined as in sinus rhythm without AA drugs, no arrhyth-
mias during serial Holter monitoring) was 48% for paroxys-
mal, 43% for persistent and 44% for longstanding persistent
AF (Table 3).
Catheter ablation was repeated in 53 patients (39%) with
paroxysmal, 39 patients (46%) with persistent and 22 patients
(46%) with longstanding persistent AF (1 redo procedure in 78
patients, 2 redo in 23 patients, 3 redo in 10 patients and 4 redo
in 3 patients) because of recurrence of AF or atrial tachycardia
(AT) after linear ablation. Reason for AF recurrence was
dominantly PV reconnection or ectopic activity in previously
non-isolated PV.
Recurrence of AF more than 12 month after the procedure
was documented in 10 patients with paroxysmal (7%), 17
patients with persistent (20%) and 12 patients with long-
standing persistent AF (25%). Five patients died during the FU,
all because of malignancy.
The success rate (defined as in sinus rhythm without AA
drugs and without arrhythmias during monitoring) after
the last procedure (mean FU 24716 month, min 6, max 90
month) was 80% for paroxysmal and 58% for persistent and
longstanding persistent AF. Additional 7% of patients (6% in
paroxysmal AF group, and 8% in persistent and longstanding
persistent AF group) were asymptomatic with documented
AF paroxysms during monitoring.
Table 1 – Clinical characteristic of the patients group (mean, min, max).
Paroxysmal Persistent Longstanding persistent Total
Patients 157 94 52 303
No of procedures 243 155 91 489
Age 56 (25–80) 56 (25–77) 58 (37–72) 57
Symptoms (years) 7 (0–41) 6(0–28) 5 (0–27) 6
Amiodaron 28 (18%) 27 (29%) 19 (37%) 74 (24%)
Betablockers 67 (43%) 46 (49%) 41 (79%) 154 (51%)
Propafenon 31 (20%) 14 (15%) 3 (6%) 48 (16%)
Sotalol 20 (13%) 12 (13%) 4 (8%) 36 (12%)
No drugs 39 (25%) 12 (13%) 1 (2%) 50 (17%)
Palpitations 147 (94%) 65 (69%) 31 (60%) 243 (80%)
Dyspnoe 67 (43%) 49 (52%) 39 (75%) 155 (51%)
Weakness 41 (26%) 21 (22%) 6 (12%) 68 (22%)
Fatigue 26 (17%) 24 (26%) 13 (25%) 63 (21%)
Chest pain 35 (22%) 11 (12%) 4 (8%) 50 (17%)
No symptoms 2 (1%) 9 (10%) 4 (8%) 15 (5%)
LA (mm) 42 (29–55) 46 (36–61) 47 (36–62) 44 (29–62)
EF (%) 64 (35–75) 59 (23–75) 51 (20–70) 60 (20–75)
Mitral regurgitation (grade 1–4) 2 (0–4) 2 (1–4) 2 (1–4) 2 (1–4)
Hypertension 87 (55%) 59 (63%) 32 (62%) 178 (59%)
IHD 10 (6%) 10 (11%) 5 (10%) 25 (8%)
Cardiomyopathy 6 (4%) 5 (5%) 13 (25%) 24 (8%)
Thyreopathy 22 (14%) 16 (17%) 8 (15%) 46 (15%)
Stroke/TIA 5 (3%) 5 (5%) 3 (6%) 13 (4%)
CHADS2 score 1 (0–5) 1 (0–3) 1 (0–4) 1 (0–5)
LA—left atrium, EF—ejection fraction, IHD—ischemic heart disease, and TIA—transitory ischemic attack.
Table 2 – Complications of catheter ablation.
Paroxysmal Persistent Longstanding persistent Total
Patients 157 94 52 303
No. of procedures 243 155 91 489
Pericardial effusion 2 2 1 5 (1.0%)
Stroke/TIA 0 1 0 1 (0.2%)
Local complication treated surgically 0 2 1 3 (0.6%)
Local complication 4 3 0 7 (1.4%)
Table 3 – Results of catheter ablation (4/2004-4/2012).
Paroxysmal Persistent Longstanding
persistent
Total
Patients 135 84 48 267
Success rate 6 month after the first procedure
SR 65 (48%) 36 (43%) 21 (44%) 122 (46%)
paroxysmal AF 67 (50%) 31 (37%) 10 (21%) 108 (40%)
AF/AT 3 (2%) 17 (20%) 17 (35%) 37 (14%)
Total success rate including redo procedures
SR 108 (80%) 49 (58%) 28 (58%) 185 (69%)
Paroxysmal AF 26 (19%) 27 (32%) 11 (23%) 64 (24%)
AF/AT 1 (1%) 8 (10%) 9 (19%) 18 (7%)
SR—sinus rhythm, AF—atrial fibrillation, and AT—atrial tachycardia.
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The EQ-5D index increased in patients with paroxysmal,
persistent, and longstanding persistent AF following CA
(from 0.79 to 0.94; from 0.81 to 0.94; and from 0.75 to 0.85
respectively, po0.05). The EQ VAS also increased in all groupsof patients after CA. (from 65 to 87; from 61 to 82; and from
55 to 74 respectively, po0.05). Significant changes on both
measures were more pronounced in patients with successful
CA than in unsuccessful patients (EQ-5D index—from 0.79 to
0.95; from 0.75 to 0.84 respectively; EQ VAS—from 64 to 88;
from 54 to 68 respectively, po0.01).
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 3 6 9 – e 3 7 4 e3734. Discussion
The left atrial anatomy is complex. A detailed understanding
of this anatomy is essential for a safe and effective AF
ablation procedure. There is a significant inter- and intra-
patient variability in the number; size and bifurcation of the
PVs. Supernumerary right PVs are present in 18–29% of the
patients, common trunk of left-sided PVs in more than 30% of
patients [5]. Higher number of left common trunk in our
group is a methodological difference, because we count also
short common trunk, which is a frequent finding in majority
of patients. Anatomical variability supports routine use of
imaging in AF ablation procedures (CT or MR image integra-
tion, intracardiac ultrasound, etc.)
Number of procedures is gradually increasing, faster
increase in our center is limited by financial resources.
Time of the procedure and x-ray time decreased gradually,
faster decrease was observed after learning curve and in case
of x-ray time also after upgrade to CARTO 3 navigation
system in March 2011.
The efficacy of AF ablation in comparison with antiarrhyt-
mic drug therapy was proved in large number of non-
randomized clinical trials and in several prospective rando-
mized clinical trials. Results of randomized trials were exam-
ined in recent meta-analyses [6]. Overall, the success rate was
77.8% in the ablation arm as compared with 23.3% in the
control group. Also recent worldwide survey monitoring out-
come and safety features of AF ablation reports a 70% efficacy
rate free of antiarrhythmic drugs and an additional 10%
efficacy rate in the presence of previously ineffective antiar-
rhythmic drugs. A second procedure was required in every
third patient and ablation of paroxysmal AF was associated
with a 35% and 66% larger probability of success as compared
to ablation of persistent and longstanding persistent AF [7].
Success rate in our group of patients is comparable with
these results. Lower numbers of first procedure success rate
and higher number of redo procedures are clearly influenced
by learning curve. We followed all patients from the begin-
ning of AF ablation procedures in our center and during
learning curve we did not achieved complete PV isolation in
many patients. Higher number of redo procedures is also
explainable by our emphasis to freedom of AF and not only to
freedom of symptoms. We recommend redo procedure also
to asymptomatic patients with AF recurrence in order to
reduce need for anticoagulation therapy.
CA of AF is one of the most complex interventional
electrophysiologic procedures and the risk associated with
AF ablation is higher than for ablation of other arrhythmias.
The overall complication rate in last worldwide survey [7] was
4.5% (25 procedure-related deaths/0.15%/, 213 episodes of
tamponade/1.31%/, 115 transient ischemic attacks/0.71%/
and 37 strokes/0.23%/). Our complication rate 3.3% per pro-
cedure (5.3% per patient) is fully comparable with published
results. Majority of our complications are local complications
in the groin. All complications were treated successfully
without further consequences. To lower complication rate
contributes use of standard technique of wide circumferen-
tial lesions with 3D navigation from the beginning and lower
power used in left atrium and especially on the posteriorwall. Lower power settings are contributive to longer proce-
dure time, but we prefer safety first principle. We also do not
count atrial tachycardia after linear ablation as complication
but as some kind of intermediate product of our ablation
between AF and sinus rhythm. Using the low power on the
posterior wall, we did not provide any other prevention of
atrioesophageal fistula than periprocedural administration of
proton pump inhibitors.
Formal assessment of quality of life has played an increas-
ingly important role in the evaluation of ablation outcomes. A
number of single-center nonrandomized studies have demon-
strated significant and sustained improvements in QoL follow-
ing catheter ablation. Also three randomized clinical trials
demonstrated superiority of CA over antiarrhythmic drug
treatment which was associated with significant improvement
QoL relative to baseline, with restoration to levels at or above
population norms [8–10]. Direct comparison with our results is
not possible because these studies used different QoL ques-
tionnaires (most often SF 36). Nevertheless, the descriptive
capacity of SF 36 and EQ-5D is similar; [11] in addition the
EQ-5D is simpler and less time-consuming (the principal factors
for our use of this generic instrument in our center). Signifi-
cantly, lower initial values in our patients with all AF subtypes
showed clear impairment of QoL before CA. After CA, the QoL of
patients with longstanding AF improved nearly to that of the
reference population, and patients with paroxysmal and per-
sistent AF improved significantly above the values of the
reference population. After successful CA, AF patients reached
highly above-average QoL values; furthermore, even patients
with persistent symptoms improved (probably because of less
frequent symptoms or better effect of AA drugs), although not
to normal values.5. Limitations
Several limitations of this study must be noted. Our single-
center non-randomized study included a small number of
patients, especially those with longstanding persistent AF.
Also, the average age of our patients is lower than in the
typical AF population. 24-month mean follow-up may be
insufficient for long-term evaluation of the effect of catheter
ablation.6. Conclusion
Despite a lot of unsolved questions is catheter ablation of AF
accepted method of treatment of symptomatic AF patients,
especially with paroxysmal form. With the standard proce-
dure we can achieve acceptable results (success rate 60–80%
with repeated procedures) with low complication rate even
in a ‘‘lower volume’’ center. CA improves QoL in our patients
with AF. As there is no gold standard to measure QoL in AF
patients, EQ-5D seems to be a simple, quick and useful tool.
Most important thing in AF patient’s management is proper
indication of ablation procedure, i.e. to select patients,
who will benefit most. According to guidelines [12], CA can
be considered in selected patients as first-line therapy for
rhythm control, i.e. those with paroxysmal AF preferring
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 3 6 9 – e 3 7 4e374interventional treatment with low risk profile for procedure-
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